Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine

Détails

ID Serval
serval:BIB_DBCADD330106
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine
Périodique
American Journal of Tropical Medicine and Hygiène
Auteur(s)
Herrera  S., Bonelo  A., Perlaza  B. L., Fernandez  O. L., Victoria  L., Lenis  A. M., Soto  L., Hurtado  H., Acuna  L. M., Velez  J. D., Palacios  R., Chen-Mok  M., Corradin  G., Arevalo-Herrera  M.
ISSN
0002-9637 (Print)
Statut éditorial
Publié
Date de publication
11/2005
Volume
73
Numéro
5 Suppl
Pages
3-9
Notes
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't --- Old month value: Nov
Résumé
Substantial experimental evidence indicates that the Plasmodium circumsporozoite (CS) protein has great potential as a vaccine candidate. We tested the safety and immunogenicity of vaccines composed of P. vivax CS-derived synthetic peptides. Sixty-nine healthy, malaria-naive volunteers were randomized to receive three injections of placebo or synthetic proteins N, R, or C (10, 30, or 100 microg/dose) in a double-blinded fashion. Vaccines were well tolerated and no serious adverse events were observed. Peptides N and R elicited humoral responses at all doses; peptide C elicicted these responses only at doses of 30 and 100 microg. The N peptide at a dose of 100 microg elicited the greatest antibody response. Antibodies to the three peptides recognized P. vivax sporozoites in an immunofluorescent antibody test. Peripheral blood mononuclear cells from most immunized volunteers also produced interferon-gamma upon peptide in vitro stimulation. These vaccines appear safe, well tolerated, and immunogenic in malaria-naive volunteers. Further optimization and development of this vaccine is being attempted to conduct phase II clinical trials.
Mots-clé
Adolescent Adult Animals Antibodies, Protozoan/*blood Double-Blind Method Female Humans Interferon Type II/metabolism Leukocytes, Mononuclear/*immunology Malaria Vaccines/administration & dosage/*adverse effects/*immunology Male Plasmodium vivax/*immunology Protozoan Proteins/*immunology Vaccines, Synthetic/administration & dosage/adverse effects/immunology
Pubmed
Web of science
Création de la notice
24/01/2008 14:55
Dernière modification de la notice
20/08/2019 16:00
Données d'usage